REAL-WORLD OUTCOMES IN PATIENTS WITH PENILE SQUAMOUS CELL CARCINOMA (PSCC) RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICI)

被引：2
|
作者：
Zhuang, Tony [1 ]
Goyal, Subir [1 ]
Brown, Jacqueline [1 ]
Carthon, Bradley [1 ]
Kucuk, Omer [1 ]
McClintock, Greta [1 ]
Yantorni, Lauren [1 ]
Bilen, Mehmet [1 ]
Master, Viraj [1 ]
Nazha, Bassel [1 ]
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
478
引用
收藏
页码：A498 / A499
页数：2
相关论文
共 50 条
  • [41] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Kang Chen
    Wei Wei
    Lei Liu
    Zhu-Jian Deng
    Le Li
    Xiu-Mei Liang
    Ping-Ping Guo
    Lu-Nan Qi
    Zhi-Ming Zhang
    Wen-Feng Gong
    Shan Huang
    Wei-Ping Yuan
    Liang Ma
    Bang-De Xiang
    Le-Qun Li
    Jian-Hong Zhong
    Cancer Immunology, Immunotherapy, 2022, 71 : 1063 - 1074
  • [42] Immune checkpoint inhibitors in sinonasal squamous cell carcinoma
    Park, Jong Chul
    Faquin, William C.
    Durbeck, Julia
    Faden, Daniel L.
    ORAL ONCOLOGY, 2020, 109
  • [43] Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors
    Hu, Xiao
    Rodday, Angie Mae
    Gurinovich, Anastasia
    Pan, Stacey
    Salei, Yana V.
    Lin, Jeffrey H.
    Byrne, Margaret M.
    Cao, Yu
    Pai, Lori
    Parsons, Susan K.
    IMMUNOTHERAPY, 2025,
  • [44] Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
    Kanjanapan, Yada
    Guduguntla, Geetha
    Varikara, Ashwati Krishnan
    Szajer, Jeremy
    Yip, Desmond
    Cockburn, John
    Fadia, Mitali
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [45] Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
    Kanjanapan, Yada
    Guduguntla, Geetha
    Varikara, Ashwati Krishnan
    Szajer, Jeremy
    Yip, Desmond
    Cockburn, John
    Fadia, Mitali
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [46] COLITIS DIAGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IN REAL-WORLD SETTINGS: TIMING OF ONSET AND PATTERNS OF CARE
    Pan, Xianying
    Yadav, Suraj
    Pathak, Raminder
    Cheng, Ben
    Monda, Stefano
    Hasan, Imran
    Lawlor, Garrett
    GASTROENTEROLOGY, 2024, 166 (05) : S1034 - S1034
  • [47] Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Cowzer, D.
    Capanu, M.
    Keane, F.
    Khalil, D.
    Shia, J.
    Do, R.
    Chou, J.
    Walch, H.
    El Dika, I.
    Yaqubie, A.
    Solit, D.
    Berger, M.
    O'Reilly, E.
    Harding, J.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S109 - S109
  • [48] IMMUNE-RELATED ADVERSE EVENTS FROM IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A REAL-WORLD EXPERIENCE
    Gampa, Anuhya
    Peeraphatdit, Thoetchai
    Charlton, Michael R.
    Pillai, Anjana A.
    HEPATOLOGY, 2020, 72 : 694A - 695A
  • [49] Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis
    Zhou, Chengjing
    Jiang, Ting
    Li, Rongzhen
    Yuan, Yan
    Xie, Weihao
    Huang, Xiaoxue
    Wang, Qiaoxuan
    Chang, Hui
    Chen, Gong
    Li, Yuhong
    Zeng, Zhifan
    Xiao, Weiwei
    Gao, Yuanhong
    CANCER COMMUNICATIONS, 2021, 41 (09) : 921 - 924
  • [50] A Real-World Comparison of the Safety Profile for Immune Checkpoint Inhibitors in Oncology Patients
    Alwhaibi, Abdulrahman
    Alenazi, Miteb A.
    Alghadeer, Sultan
    Mansy, Wael
    Alsaif, Reem A.
    Abualreesh, Nawaf E.
    Alanazi, Rakan J.
    Alroumi, Abdullah
    Alanazi, Saleh A.
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (02)
12345